David Jaraj1,2, Jonas Höijer3, Linnea Widman3, Johan Ahlgren4,5, Lars-Gunnar Arnesson6, Zakaria Einbeigi7,8, Marie Klintman9, Eva Vikhe Patil6, Malin Sund10, Irma Fredriksson11,12, Jonas Bergh12,13,1,4, Pettersson Andreas1. 1. Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden. 2. Department of Surgery, Capio St Görans Hospital, Stockholm, Sweden. 3. Unit of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. 4. Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden. 5. Regional Cancer Centre, Uppsala Örebro Health Care Region, Uppsala, Sweden. 6. Department of Surgery, University Hospital, Linköping, Sweden. 7. Department of Medicine, Southern Älvsborg Hospital, Borås, Sweden. 8. Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, Gothenburg, Sweden. 9. Department of Oncology and Radiation Physics, Skåne University Hospital, Lund University, Lund, Sweden. 10. Department of Surgical and Perioperative Sciences/Surgery, Umeå University, Umeå, Sweden. 11. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. 12. Department of Breast, Endocrine and Sarcoma Surgery, Karolinska University Hospital, Stockholm, Sweden. 13. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Abstract
Background: Although small, node-negative breast cancer (ie, T1abN0) constitutes 20% of all newly diagnosed breast cancers, data on prognosis and prognostic factors are limited. Methods: We conducted a population-based cohort study including 20 114 Swedish women treated for T1abN0 breast cancer from 1977 onward. Patient and tumor data were collected from Swedish breast cancer registries. Cohort subjects were followed through linkage to the Cause of Death Register. We calculated the cumulative incidence of breast cancer-specific and overall death and used Cox regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Results: During a median follow-up of 9.1 years (range = 0-38), 915 women died of breast cancer and 5416 of any cause. The 10-, 20-, and 30-year cumulative incidences of breast cancer death were 3.4% (95% CI = 3.1% to 3.7%), 7.6% (95% CI = 7.1% to 8.2%), and 10.5% (95% CI = 9.6% to 11.4%), respectively. The multivariable hazard ratios and 95% confidence intervals of breast cancer death were 0.92 (95% CI = 0.88 to 0.97) for each additional calendar year of diagnosis, 4.38 (95% CI = 2.79 to 6.87) for grade 3 vs grade 1 tumors, 0.43 (95% CI = 0.31 to 0.62) for progesterone receptor-positive vs progesterone receptor-negative disease, and 2.01 (95% CI = 0.99 to 4.07) for HER2-positive vs HER2-negative disease. Women with grade 3 vs grade 1 tumors had a 56% increased risk of death from any cause (HR = 1.56, 95% CI = 1.30 to 1.88). Conclusions: The risk of breast cancer death in T1abN0 disease continues to increase steadily beyond 10 years after diagnosis, has improved over time, and varies substantially by tumor characteristics.
Background: Although small, node-negative breast cancer (ie, T1abN0) constitutes 20% of all newly diagnosed breast cancers, data on prognosis and prognostic factors are limited. Methods: We conducted a population-based cohort study including 20 114 Swedish women treated for T1abN0 breast cancer from 1977 onward. Patient and tumor data were collected from Swedish breast cancer registries. Cohort subjects were followed through linkage to the Cause of Death Register. We calculated the cumulative incidence of breast cancer-specific and overall death and used Cox regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Results: During a median follow-up of 9.1 years (range = 0-38), 915 women died of breast cancer and 5416 of any cause. The 10-, 20-, and 30-year cumulative incidences of breast cancer death were 3.4% (95% CI = 3.1% to 3.7%), 7.6% (95% CI = 7.1% to 8.2%), and 10.5% (95% CI = 9.6% to 11.4%), respectively. The multivariable hazard ratios and 95% confidence intervals of breast cancer death were 0.92 (95% CI = 0.88 to 0.97) for each additional calendar year of diagnosis, 4.38 (95% CI = 2.79 to 6.87) for grade 3 vs grade 1 tumors, 0.43 (95% CI = 0.31 to 0.62) for progesterone receptor-positive vs progesterone receptor-negative disease, and 2.01 (95% CI = 0.99 to 4.07) for HER2-positive vs HER2-negative disease. Women with grade 3 vs grade 1 tumors had a 56% increased risk of death from any cause (HR = 1.56, 95% CI = 1.30 to 1.88). Conclusions: The risk of breast cancer death in T1abN0 disease continues to increase steadily beyond 10 years after diagnosis, has improved over time, and varies substantially by tumor characteristics.
Authors: Rachel L Theriault; Jennifer K Litton; Elizabeth A Mittendorf; Huiqin Chen; Funda Meric-Bernstam; Mariana Chavez-Macgregor; Phuong K Morrow; Wendy A Woodward; Aysegul Sahin; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo Journal: Clin Breast Cancer Date: 2011-07-20 Impact factor: 3.225
Authors: Hongchao Pan; Richard Gray; Jeremy Braybrooke; Christina Davies; Carolyn Taylor; Paul McGale; Richard Peto; Kathleen I Pritchard; Jonas Bergh; Mitch Dowsett; Daniel F Hayes Journal: N Engl J Med Date: 2017-11-09 Impact factor: 91.245
Authors: Stephen K Chia; Caroline H Speers; Cicely J Bryce; Malcolm M Hayes; Ivo A Olivotto Journal: J Clin Oncol Date: 2004-05-01 Impact factor: 44.544
Authors: R Peto; C Davies; J Godwin; R Gray; H C Pan; M Clarke; D Cutter; S Darby; P McGale; C Taylor; Y C Wang; J Bergh; A Di Leo; K Albain; S Swain; M Piccart; K Pritchard Journal: Lancet Date: 2011-12-05 Impact factor: 79.321
Authors: Hannah Louise Brooke; Mats Talbäck; Jesper Hörnblad; Lars Age Johansson; Jonas Filip Ludvigsson; Henrik Druid; Maria Feychting; Rickard Ljung Journal: Eur J Epidemiol Date: 2017-10-05 Impact factor: 8.082
Authors: Gunilla Rask; Anoosheh Nazemroaya; Malin Jansson; Charlotta Wadsten; Greger Nilsson; Carl Blomqvist; Lars Holmberg; Fredrik Wärnberg; Malin Sund Journal: Breast Cancer Res Treat Date: 2022-08-06 Impact factor: 4.624